Development of Novel Clinical Endpoints in Intermediate AMD

Active, not recruitingOBSERVATIONAL
Enrollment

718

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Age Related Macular Degeneration (AMD)
Interventions
OTHER

No intervention

According to clinical practice.

Trial Locations (20)

Unknown

Righospitalet Copenhagen, Copenhagen

Centre Hospitalier Intercommunal de Creteil, Créteil

Centre d'Investigation Clinique Centre National d'Ophtalmologie des Quinze-Vingts, Paris

University Hospital Bonn, Bonn

University Hospital Cologne, Cologne

Department of Ophthalmology, University of Freiburg, Freiburg im Breisgau

University Eye Hospital Munich, Munich

St. Franziskus Hospital, Münster

Universtiy Hospital Tuebingen, Tübingen

University Eye Hospital Ulm, Ulm

Luigi Sacco Hospital, Milan

Ospedale San Raffaele, Milan

G.B.Bietti Eye Foundation, Rome

Radboud University Medical Centre, Leiden

Radboud University Medical Centre, Nijmegen

Centre for Clinical Trials, AIBILI, Coimbra

Centro Hospitalar de São João, E.P.E., Porto

Queen's University Belfast, Belfast

Gloucestershire Hospitals NHS Foundation Trust, Gloucester

Moorfields Eye Hospital, London

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Association for Innovation and Biomedical Research on Light and Image

OTHER

collaborator

City, University of London

OTHER

collaborator

European Clinical Research Infrastructure Network

OTHER

collaborator

La Fondation Voir et Entendre

UNKNOWN

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Radboud University Medical Center

OTHER

collaborator

University of Sheffield

OTHER

collaborator

University College, London

OTHER

collaborator

Carl Zeiss Meditec AG

INDUSTRY

collaborator

Innovative Medicines Initiative

OTHER

lead

Frank G. Holz

OTHER